Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, is pleased to announce that has finalized a self-led financing round of EUR 3.6m with existing and new shareholders. Matisse received the funding from Brightlands Venture Partners, private investment companies, informal investors and the management team. See full press release in this post for more information.
Super leuk om te lezen gefeliciteerd
Congratulations Gerry Nicolaes and team
Congrats Peter and team!
Democratizing data-driven medicine
1yCongratulations! I look forward to speaking with Matisse at Bio-Rad's digital PCR and flow cytometry event in Utrecht on January 30th.